ZEB1 and sarcoma: On one hand, GRHL2 directly suppresses the expression of the EMT inducer ZEB1 in breast (Cieply et al., 2012; Werner et al., 2013), ovarian (Chung et al., 2016), bladder cancers (Shen et al., 2020), and sarcoma (Somarelli et al., 2016).